Medical Editor: John P. Cunha, DO, FACOEP
Anascorp [Centruroides (Scorpion) Immune F(ab')2 (Equine)] is an antivenom indicated for treatment of clinical signs of scorpion venom poisoning (envenomation). Common side effects of Anascorp include:
- runny nose
- muscle pain
- diarrhea, and
The initial dose of Anascorp is 3 vials given as soon as possible after scorpion sting in patients who develop clinically important signs of envenomation. Anascorp may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Anascorp should be administered only if needed; it is unknown if it would harm a fetus. It is unknown if Anascorp passes into breast milk. Consult your doctor before breastfeeding.
Our Anascorp [Centruroides (Scorpion) Immune F(ab')2 (Equine)] Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The most common adverse reactions observed in ≥2% of patients in the clinical studies for Anascorp were: vomiting, pyrexia, rash, nausea, and pruritus.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials o f a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 1534 patients were treated with Anascorp, ranging from less than one month to 90 years old. The patient population was comprised of 802 males and 732 females. Patients were monitored for signs and symptoms of adverse reactions, including acute hypersensitivity reactions and serum sickness. Follow-up telephone interviews were conducted at 24 hours, 7 days, and 14 days after treatment to assess symptoms suggestive of ongoing venom effect, serum sickness, and any other adverse reactions
Table 1 shows the adverse reactions occurring in patients across all clinical trials for Anascorp. Twenty-seven percent (421/1534) o f patients receiving Anascorp reported at least one adverse reaction.
Table 1: Adverse Reactions Reported in ≥1
% of Patients
No patients died or discontinued study participation for severe adverse reactions.
Eight patients were considered to have serum sickness (Type HI hypersensitivity); no patient manifested the full serum sickness syndrome. Three patients were treated with systemic corticosteroids and five others received either no treatment or symptomatic therapy.
34 patients experienced a total of 39 severe adverse reactions such as respiratory distress, aspiration, hypoxia, ataxia, pneumonia, and eye swelling. It is not clear whether these adverse reactions were related to Anascorp, envenomation, or a combination o f both.
The following adverse reactions have been identified during post approval use of Anascorp. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Chest tightness, palpitations, rash and pruritus.
Read the entire FDA prescribing information for Anascorp (Anascorp Centruroides (Scorpion) Immune F(ab' )2 (Equine) Injection)